Clinical Trial Update: Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating addition of M3814 (Peposertib) to Lutetium-177 dotatate for pancreatic neuroendocrine tumors; study currently active but not recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Lutetium-177 dotatate (Lutetium-177 dotatate)
• Peposertib (Peposertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neuroendocrine Neoplasm | Phase 1 | Status: ACTIVE_NOT_RECRUITING